Report Description Table of Contents Human Papillomavirus (HPV) Vaccine Market: How Are National Immunization Programs and New Suppliers Reshaping Growth? – (Updated On: 19th-Nov-2026) According to Strategic Market Research, the Global Human Papillomavirus (HPV) Vaccine Market was valued at USD 7.645 billion in 2025 and is projected to reach USD 12.795 billion by 2032, growing at a CAGR of 7.63% during 2026–2032. Growing government investment in HPV vaccination, wider immunization coverage, and the introduction of vaccines by new manufacturers are supporting market expansion. National vaccination programs remain the largest source of demand, while competition among suppliers is increasing as countries seek affordable vaccines and reliable long-term supply. Global HPV vaccination programs continued to expand in 2025. According to the World Health Organization's July 2026 update, 33% of girls worldwide had received at least one HPV vaccine dose by age 15. HPV vaccination was included in national immunization programs and services across 162 countries, with 15 countries introducing vaccination during the year. The continued expansion of national programs is creating new purchasing opportunities for HPV vaccine manufacturers, particularly in countries working to improve adolescent vaccination coverage. International vaccination initiatives are generating substantial demand for HPV vaccines. According to Gavi's 2025 annual progress report, published in 2026, more than 35 million girls received complete HPV vaccination with Gavi support during 2025. By the end of the year, 53 countries had introduced national HPV vaccination programs with the organization's assistance. The expansion of these programs is creating opportunities for manufacturers supplying vaccines through government contracts and international procurement arrangements, particularly in countries where public financing supports vaccination access. Cervical cancer prevention remains a major priority for HPV vaccination programs. The World Health Organization's global cervical cancer elimination strategy aims to achieve 90% HPV vaccination coverage among girls by age 15 by 2030. With vaccination coverage remaining below this target, governments continue to prioritize HPV vaccine access and adolescent immunization. The introduction of vaccination programs in additional countries and efforts to reach previously unvaccinated adolescents are expected to support further vaccine purchasing. Competition in the HPV vaccine market is increasing as new manufacturers expand their product offerings and seek access to international immunization programs. Nonavalent vaccines maintain a strong position in established markets because of their broader HPV type coverage, while bivalent and quadrivalent products remain important options for government-funded vaccination. The availability of additional suppliers is increasing procurement choices and competition on vaccine pricing. Through 2032, market performance will be influenced by national vaccination expansion, government purchasing commitments, and manufacturers' ability to secure supply agreements. Overall, HPV vaccine market growth through 2032 will depend on expanding vaccination coverage, procurement commitments, competition between vaccine manufacturers, and changes in dosing policy. Established nonavalent vaccines benefit from broad type coverage, while new manufacturing entrants and affordable vaccine products are increasing competition in publicly funded markets. Suppliers with reliable production, competitive procurement pricing, and access to national immunization programs will be positioned to capture additional demand, although coverage growth will not necessarily translate into an equivalent increase in vaccine doses or revenue. Which Segments Are Leading the Human Papillomavirus (HPV) Vaccine Market and Which Are Emerging as the Fastest Expanding Opportunities? Vaccine Type: Nonavalent Vaccines Account for the Largest Revenue Share Nonavalent vaccines account for 65% of global HPV vaccine revenue, equivalent to USD 4.969 billion in 2025, and are projected to grow at a CAGR of 8.50% during 2026–2032. Their leading position reflects protection against nine HPV types, including seven cancer-associated types and two associated with genital warts. The category is established in vaccination markets that prioritize broader protection. Its future competitive landscape is changing as additional nine-valent products receive national authorization and pursue international regulatory recognition. Quadrivalent vaccines contribute 23% of market revenue, equivalent to USD 1.758 billion in 2025, and are projected to expand at a CAGR of 5.50%. Protection against HPV types 6, 11, 16, and 18 supports their use in programs addressing both cancer-associated infections and genital warts. Their commercial relevance extends to government procurement markets where vaccine coverage, price, and availability influence purchasing decisions. Recent additions to the internationally recognized vaccine supply base are strengthening competition in this category. Bivalent vaccines represent 12% of revenue, equivalent to USD 0.917 billion in 2025, and are projected to grow at a CAGR of 6.66%. The category remains commercially relevant because HPV types 16 and 18 are major targets of cervical cancer prevention programs. China's 2026 national immunization schedule specifies a two-dose bivalent HPV vaccination series for girls aged 13, with a six-month interval. The policy demonstrates that government purchasing can favor targeted HPV protection rather than higher-valency products, making bivalent vaccines commercially significant despite their smaller revenue contribution. Technology: VLP-Based Vaccines Maintain the Established Commercial Position Virus-like particle (VLP)-based vaccines account for 91% of the supplied technology allocation, equivalent to USD 6.957 billion in 2025, and are projected to grow at a CAGR of 7.80%. Licensed preventive HPV vaccines use recombinant VLP technology, with commercial differences arising from production platforms, antigen coverage, vaccine presentations, and manufacturer supply capabilities. The WHO's vaccine product comparison identifies differences in storage requirements, packaging, and dosage presentations that are relevant to country procurement decisions. Other recombinant protein-based approaches account for the remaining 9% of the supplied allocation, equivalent to USD 0.688 billion, with a projected CAGR of 5.87%. However, current WHO product information does not establish a separate commercial market of this size for licensed preventive HPV vaccines using non-VLP technology. This allocation should be retained only as a Strategic Market Research classification, rather than presented as independently verified sales. The established commercial market remains concentrated in VLP-based preventive vaccines. Indication: Cervical Cancer Prevention Leads Vaccine Utilization Cervical cancer prevention accounts for the largest indication allocation at 72%, equivalent to USD 5.504 billion in 2025, and is projected to grow at a CAGR of 7.50%. Its commercial position is supported by national vaccination policies targeting adolescent girls and international cervical cancer elimination commitments. The WHO and UNICEF's July 2026 HPV coverage analysis identified 22.8 million girls living in countries where HPV vaccination was not included in the national program during 2025. This identifies a substantial population outside routine national vaccination access and a potential source of future public procurement as additional countries introduce programs. Anal cancer prevention represents 12% of the supplied indication allocation, equivalent to USD 0.917 billion in 2025, and is projected to register the fastest CAGR of 9.00%. Its commercial relevance is associated with HPV vaccination for both sexes, particularly in countries extending eligibility beyond adolescent girls. The WHO and UNICEF reported in their 2026 analysis that 87 countries had included boys in their HPV vaccination policies by the end of 2025. These policies expand the eligible population for protection against HPV-associated cancers affecting males, including anal cancer. Genital warts prevention accounts for 10% of revenue, equivalent to USD 0.764 billion in 2025, and is projected to grow at a CAGR of 6.00%. Quadrivalent and nonavalent vaccines offer protection against HPV types 6 and 11, which cause most genital warts. This additional preventive benefit differentiates these products from bivalent vaccines and can influence product selection in gender-neutral vaccination programs. Other HPV-associated cancers contribute 6% of the supplied allocation, equivalent to USD 0.459 billion in 2025, and are projected to expand at 8.96%. The category includes penile, vaginal, vulvar, and certain oropharyngeal cancers. Its commercial contribution is linked to broad HPV vaccination eligibility rather than separate purchasing for each cancer. Because a vaccine can prevent infections associated with several diseases, these indication shares represent an allocation of the same preventive vaccine market, not independently reported sales by disease. End User: Government Programs Dominate Vaccine Purchasing Government immunization programs account for 71% of market revenue, equivalent to USD 5.428 billion in 2025, and are projected to grow at a CAGR of 7.80%. Public purchasing is supported by routine adolescent immunization, school vaccination, and national vaccine supply contracts. WHO prequalification is important for internationally supported purchasing because it establishes product eligibility for relevant procurement channels. National product choices can differ substantially, with some countries purchasing broader-valency vaccines and others prioritizing lower-cost bivalent or quadrivalent products. Hospitals contribute 19% of revenue, equivalent to USD 1.453 billion in 2025, and are projected to expand at 6.90%. Their contribution includes vaccination services for eligible adolescents and adults, particularly where hospital-based preventive care is part of the country's immunization delivery system. Hospital purchases may also include vaccines financed through government programs. Consequently, this end-user classification requires a consistent distinction between the organization administering a vaccine and the institution financing its purchase. Clinics represent 10% of revenue, equivalent to USD 0.764 billion in 2025, and are projected to record the fastest end-user CAGR of 7.82%. Their commercial contribution is associated with outpatient HPV vaccination, catch-up services, and healthcare provider referrals. In countries permitting vaccination outside school-based programs, clinics provide additional access for eligible individuals who missed routine adolescent immunization. Vaccine purchasing through this channel depends on national reimbursement arrangements, private payment, and the products authorized for the relevant age groups. Which Regions and Countries Present the Strongest HPV Vaccine Market Opportunities? North America — Largest Regional Market North America accounts for 35% of global HPV vaccine revenue, equivalent to USD 2.676 billion in 2025, and is projected to grow at a CAGR of 6.20% during 2026–2032. The United States contributes the largest share of regional demand through routine adolescent immunization, public vaccine purchasing, and private healthcare vaccination services. Its established market position is supported by national vaccination recommendations, although recent coverage data indicate that further growth requires improvements in vaccination participation rather than reliance on existing immunization infrastructure. United States: The country accounts for 28% of global market revenue, equivalent to USD 2.141 billion in 2025, and is projected to grow at 6.20%. According to the CDC's September 2026 report, 77.7% of adolescents aged 13–17 received at least one HPV vaccine dose in 2025, while 63.4% were up to date with their recommended vaccinations. HPV vaccination coverage had not increased for four consecutive years. This indicates continued demand potential among adolescents who have not initiated or completed vaccination, particularly through pediatric practices and catch-up immunization services. Europe — Established Vaccination Programs and Product-Specific Procurement Europe accounts for 26% of global market revenue, equivalent to USD 1.988 billion in 2025, and is projected to grow at a CAGR of 6.90%. Demand is concentrated in publicly financed vaccination programs, including countries providing routine HPV vaccination to both girls and boys. National coverage and vaccine procurement differ between countries, making product selection and immunization participation important influences on regional performance. United Kingdom: The UK Health Security Agency's January 2026 report found that HPV vaccine uptake by Year 10 in England was 75.5% among girls and 70.5% among boys for the 2024–2025 academic year. The difference between the two groups indicates continuing opportunities to improve participation in England's gender-neutral vaccination program. School-based immunization remains an important purchasing channel, while vaccination of eligible adolescents who missed routine appointments contributes additional demand. Asia-Pacific — Fastest-Growing Regional Market Asia-Pacific represents 27% of global HPV vaccine revenue, equivalent to USD 2.064 billion in 2025, and is projected to record the fastest regional CAGR of 9.80%. The region includes established vaccination markets, countries introducing publicly financed programs, and emerging domestic vaccine manufacturers. Differences in national purchasing policies create opportunities across bivalent, quadrivalent, and nonavalent vaccines. India: The country accounts for 4% of global revenue, equivalent to USD 0.306 billion in 2025, and is projected to register a CAGR of 12.50%. India's nationwide free HPV vaccination campaign began on February 28, 2026, targeting girls aged 14. According to the Ministry of Health and Family Welfare's September 2026 announcement, more than 8 million HPV vaccine doses had been administered by September 11. Uttar Pradesh accounted for more than 2.2 million vaccinations. The campaign provides direct evidence of large-scale government vaccine utilization and establishes a recurring purchasing requirement for eligible adolescent cohorts. Australia: The Australian Institute of Health and Welfare's November 2026 report reported HPV vaccination coverage of 78.7% among girls and 75.6% among boys turning 15 in 2025. Australia requires one dose of Gardasil 9 for most eligible individuals up to age 25, demonstrating the commercial significance of simplified vaccination schedules in an established gender-neutral market. Recent coverage results identify opportunities to improve participation, although fewer required doses per recipient affect the relationship between coverage and vaccine purchasing volumes. Latin America — Public Vaccination and Adolescent Catch-Up Programs Latin America contributes 7% of global market revenue, equivalent to USD 0.535 billion in 2025, and is projected to grow at a CAGR of 8.80%. Public purchasing remains the principal commercial opportunity, particularly where national vaccination policies extend access to adolescents who missed routine vaccination. Brazil: The Brazilian Ministry of Health's October 2026 update confirmed that HPV vaccination for previously unvaccinated individuals aged 15–19 would remain available through December 31, 2026. The program extends access beyond the routine 9–14-year-old population through Brazil's Unified Health System. This creates an identifiable additional purchasing requirement associated with catch-up immunization. Its long-term revenue contribution will depend on the number of eligible individuals vaccinated and the continuation of publicly financed access. Middle East & Africa — New Programs and Expanding School-Based Vaccination The Middle East & Africa accounts for 5% of global HPV vaccine revenue, equivalent to USD 0.382 billion in 2025, and is projected to grow at a CAGR of 6.90%. Regional purchasing opportunities are concentrated in national program introductions, school-based immunization, and vaccine supply supported by international financing. South Africa: According to the South African Department of Health's November 17, 2026 announcement, the country's February–March 2026 school vaccination campaign reached 428,395 girls in Grades 5–7, achieving 90.6% campaign coverage. The government has also expanded vaccination access to girls attending private schools and is working to reach those who missed previous campaigns. These developments demonstrate active vaccine utilization and a defined opportunity for additional purchasing through broader school participation. Burundi: On April 29, 2026, the government introduced HPV vaccination with support from Gavi, UNICEF, and WHO. The introduction establishes a new national market for HPV vaccine purchasing and reflects the continuing expansion of preventive vaccination in African countries that previously lacked routine HPV immunization. What Are the Key Factors Driving the Global HPV Vaccine Market? Expansion of Publicly Funded HPV Vaccination Government purchasing continues to be a central contributor to HPV vaccine demand as countries introduce national vaccination programs and extend access to additional adolescent cohorts. Public procurement creates opportunities for substantial vaccine supply contracts, but national product choices vary according to vaccine price, available funding, and the number of doses required. The commercial importance of these decisions is particularly visible in countries adopting different vaccination schedules and product categories. Some national programs prioritize bivalent vaccines for cervical cancer prevention, while others purchase quadrivalent or nonavalent products. Manufacturers therefore compete not only on the range of HPV types covered but also on their ability to meet national tender requirements and maintain reliable supplies. Increasing Use of Single-Dose Vaccination Single-dose vaccination is changing HPV vaccine purchasing requirements. The WHO reported in July 2026 that 93 countries had adopted single-dose HPV vaccination schedules by the end of 2025, and more than 85% of vaccinated girls aged 9–14 were receiving vaccination under these schedules. The change can help governments vaccinate more eligible individuals with available supplies and reduce administration costs. For manufacturers, however, fewer doses per recipient can reduce the volume required to vaccinate a given population. As a result, expanded vaccination eligibility, new national program introductions, and negotiated vaccine prices are becoming increasingly important to revenue growth. Growth in International Procurement Eligibility WHO prequalification is an important commercial requirement for manufacturers seeking access to internationally supported vaccine purchasing. Product reviews assess quality, safety, efficacy, and manufacturing requirements, while procurement agencies also consider vaccine presentation and supply arrangements. The increasing number of qualified HPV vaccine products expands purchasing options for governments and international organizations. Additional suppliers can reduce dependence on individual manufacturers and create competition in price-sensitive immunization markets. For vaccine producers, successful regulatory qualification provides access to potential customers but does not guarantee procurement contracts or sales volumes. Expansion of Gender-Neutral and Catch-Up Vaccination Countries vaccinating both girls and boys have a wider eligible population than programs targeting girls alone. Gender-neutral vaccination also strengthens the preventive role of HPV vaccines against cancers and genital warts affecting males. Catch-up vaccination creates a separate source of demand among individuals who missed routine adolescent immunization. The commercial opportunity varies by national eligibility rules, age limits, reimbursement coverage, and vaccine availability. Countries expanding these services may require additional doses beyond regular annual school cohorts, although the duration of catch-up programs can make purchasing demand less predictable. Which Companies Are Competing in the Human Papillomavirus (HPV) Vaccine Market? Merck & Co., Inc. — Established Commercial HPV Vaccine Supplier Merck maintains a prominent position through its GARDASIL and GARDASIL 9 portfolio. According to the company's October 2026 financial results, combined worldwide sales of these HPV vaccines reached USD 1.995 billion in Q3 2026, compared with USD 1.749 billion in Q3 2025, representing 14% year-over-year growth. The company attributed the increase primarily to favorable U.S. public-sector purchasing patterns and higher net prices. These figures directly establish the commercial scale of its HPV vaccine portfolio, but they do not separately disclose nonavalent vaccine revenue or establish the total size of any regional market. GSK plc — Established Bivalent HPV Vaccine Developer GSK developed Cervarix, which targets HPV types 16 and 18 and has historically been used in cervical cancer prevention. Its current competitive position differs across national markets. The UK government's October 2026 vaccine supply update confirms that Cervarix has been discontinued in the United Kingdom. This distinction is important when assessing competition: historical product approvals and manufacturer participation do not establish continued commercial sales in every market. Xiamen Innovax Biotech — Expanding into Nonavalent Vaccine Competition Xiamen Innovax participates through the WHO-prequalified bivalent vaccine Cecolin and is advancing Cecolin 9 toward international market access. In 2026, the company announced submission of its nine-valent vaccine for WHO prequalification following Chinese approval in 2025. The application creates a potential opportunity to compete in internationally supported nonavalent vaccine procurement, subject to successful regulatory review. Its existing bivalent product establishes commercial participation, while the additional vaccine could broaden the company's portfolio beyond cervical cancer-focused products. Walvax Biotechnology — Additional Bivalent HPV Vaccine Supply Walvax Biotechnology participates through Walrinvax, manufactured by its associated company Yuxi Zerun Biotechnology. The vaccine holds current WHO prequalification and is available as a single-dose-vial product requiring refrigerated storage at 2–8°C. The WHO product record confirms its eligibility status and presentation. This provides an additional procurement option within the bivalent category, where purchasing agencies compare product price, availability, packaging, and supply commitments. Serum Institute of India — Expanding Quadrivalent Vaccine Supply The Serum Institute of India manufactures CERVAVAC, a quadrivalent HPV vaccine that received WHO prequalification on September 25, 2026. The WHO prequalification record identifies a single-dose-vial presentation, while a separate approved presentation contains two doses per vial. These packaging alternatives provide different options for national vaccination programs and institutional purchasers. The qualification strengthens the company's eligibility for international procurement, although actual commercial participation depends on purchasing agreements and manufacturing supply commitments. What Will Shape HPV Vaccine Market Growth Through 2032? The Global HPV Vaccine Market is projected to generate approximately USD 5.15 billion in additional annual revenue by 2032. The strongest product opportunity remains in nonavalent vaccines, while public immunization programs continue to account for the largest purchasing channel. Asia-Pacific offers the fastest projected regional expansion, reflecting new national programs, an expanding manufacturer base, and differences in vaccine affordability. Recent regulatory and procurement developments demonstrate that commercial growth will not be determined by vaccination coverage alone. New internationally qualified suppliers are increasing competition, national immunization programs are selecting products with different HPV type coverage, and single-dose schedules are reducing the number of doses required for many eligible individuals. The principal revenue opportunities are therefore concentrated in additional government procurement, broader vaccination eligibility, competitive vaccine supply, and participation in national immunization programs. Manufacturers must also account for potential pricing pressure and the effect of simplified vaccination schedules on dose volumes. Research Methodology: How Are Vaccination Data, Procurement Records, and Manufacturer Disclosures Assessed? The Global HPV Vaccine Market assessment covers preventive HPV vaccines supplied through government immunization programs, hospitals, clinics, and other eligible vaccination channels. Vaccine type, technology, indication, end-user, and regional classifications represent separate allocations of the same overall market. The assessment considers product-specific manufacturer disclosures, national HPV vaccination data, government procurement developments, WHO prequalification records, vaccine product presentations, and regulatory information. Company vaccine sales are treated as direct evidence of that manufacturer's commercial activity and are not used independently to substantiate regional leadership or the revenue share of individual vaccine types. The supplied market shares and segment growth rates reconcile mathematically with the global 2032 forecast, subject to rounding. However, the underlying product-level sales volumes, average selling prices, and procurement data used to derive the original market valuation were not supplied for independent verification. The cited public sources therefore support the commercial analysis without being presented as proof of the original market-sizing inputs. Human Papillomavirus (HPV) Vaccine Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 7.645 Billion Revenue Forecast in 2032 USD 12.795 Billion Overall Growth Rate CAGR of 7.63% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Vaccine Type, By Technology, By Indication, By End User, By Geography By Vaccine Type Nonavalent Vaccines, Quadrivalent Vaccines, Bivalent Vaccines By Technology VLP-Based Vaccines, Other Recombinant Protein-Based Approaches By Indication Cervical Cancer Prevention, Anal Cancer Prevention, Genital Warts Prevention, Other HPV-Associated Cancer Prevention By End User Government Programs, Hospitals, Clinics By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Expansion of national HPV vaccination programs, government immunization investment, wider adolescent vaccination coverage, international vaccination initiatives, entry of additional vaccine manufacturers Customization Option Available upon request Frequently Asked Question About This Report Q1. How are expanding vaccination programs influencing demand in the HPV vaccine market? A1. National immunization programs and international vaccination initiatives are increasing vaccine procurement. WHO reported that 162 countries included HPV vaccination in national programs by 2025, while Gavi supported complete vaccination of more than 35 million girls during the year. These developments are creating additional supply opportunities for vaccine manufacturers. Q2. What regulatory developments are changing competition in the industry? A2. WHO prequalification is allowing more manufacturers to compete for international vaccine contracts. The Serum Institute of India's CERVAVAC received WHO prequalification in September 2026, while Xiamen Innovax is seeking international qualification for its nine-valent vaccine. These developments could increase vaccine availability and strengthen pricing competition. Q3. Which regions are expected to generate the strongest growth in the market? A3. Asia-Pacific is projected to record the fastest regional CAGR of 9.8% through 2032. India is expected to grow at 12.5%, supported by its nationwide free HPV vaccination campaign launched in February 2026. More than 8 million doses had been administered in India by September 11, 2026. Q4. How are changing vaccination schedules influencing the industry? A4. Single-dose schedules are changing vaccine purchasing requirements by reducing the number of doses needed per recipient. WHO reported that 93 countries had adopted single-dose HPV vaccination schedules by the end of 2025. This approach can expand vaccination coverage but may reduce dose volumes per vaccinated person, making procurement pricing and eligibility expansion important commercial factors. Q5. What are the major revenue opportunities available in the HPV vaccine market? A5. Nonavalent vaccines represent the largest product opportunity, accounting for an estimated 65% revenue share in 2025. Government immunization programs generate approximately 71% of vaccine revenue. Expanding gender-neutral vaccination and catch-up programs creates additional opportunities for manufacturers participating in national procurement contracts. Q6. How are manufacturers strengthening their position in the industry? A6. Vaccine manufacturers are expanding product coverage and international procurement eligibility. Merck maintains a strong position through GARDASIL and GARDASIL 9, reporting USD 1.995 billion in combined sales during Q3 2026. Walvax supplies WHO-prequalified bivalent vaccines, while Serum Institute of India is expanding international access to its quadrivalent CERVAVAC product. Sources: World Health Organization – July 2026 Update Reports 33% Global First-Dose HPV Vaccination Coverage Among Girls in 2025, With Vaccination Available Through National Programs in 162 Countries WHO – Immunization Coverage: HPV Vaccination Uptake and National Program Expansion WHO and UNICEF – July 2026 Estimates Confirm That 93 Countries Implemented Single-Dose HPV Schedules and 87 Included Boys in Vaccination Programs by the End of 2025 WHO/UNICEF – HPV Vaccine Coverage Estimates: Dosing Policies and Gender-Neutral Vaccination U.S. CDC – September 2026 Report Finds That 77.7% of Adolescents Aged 13–17 Had Received at Least One HPV Vaccine Dose in 2025, While 63.4% Were Up to Date CDC – National Immunization Survey–Teen: U.S. HPV Vaccination Coverage in 2025 India’s Ministry of Health and Family Welfare – Reported More Than 8 Million HPV Vaccine Doses Administered by September 11, 2026, Under the National Campaign for 14-Year-Old Girls Government of India – National HPV Vaccination Campaign Reaches 80 Lakh Doses World Health Organization – Granted Prequalification to Serum Institute of India’s Quadrivalent CERVAVAC Vaccine Effective September 25, 2026 WHO – CERVAVAC: Manufacturer, Vaccine Type, and Current Prequalification Status Merck & Co. – Reported Combined GARDASIL and GARDASIL 9 Worldwide Sales of USD 1.995 Billion in Q3 2026, Up 14% From Q3 2025 Merck – Third-Quarter 2026 Results: HPV Vaccine Sales and Public-Sector Purchasing Trends UK Health Security Agency – January 2026 Report Records HPV Vaccine Uptake of 75.5% Among Year 10 Girls and 70.5% Among Boys in England During 2024–2025 UKHSA – HPV Vaccination Coverage and School-Leaver Catch-Up Opportunities UK Health Security Agency – October 2026 Supply Update Confirms Gardasil 9 Availability and Discontinuation of Cervarix in the United Kingdom UK Government – October 2026 Vaccine Update: HPV Vaccine Supply Status Australian Institute of Health and Welfare – November 2026 Report Records HPV Vaccination Coverage of 78.7% Among Girls and 75.6% Among Boys Turning 15 in 2025 AIHW – National Cervical Screening Program Monitoring Report 2026: HPV Vaccination Coverage Table of Contents - Global Human Papillomavirus (HPV) Vaccine Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Vaccine Type, Technology, Indication, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Vaccine Type, Technology, Indication, End User, and Region National Immunization Program Expansion and New Supplier Participation Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Vaccine Type, Technology, Indication, and End User Competitive Positioning of Nonavalent, Quadrivalent, and Bivalent Vaccines Market Share Trends Across Public Immunization and Healthcare Delivery Channels Investment Opportunities in the Human Papillomavirus (HPV) Vaccine Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Nonavalent Vaccine Development and Affordable Vaccine Supply Expansion of National Immunization Programs and Government Procurement Opportunities in WHO-Prequalified Vaccines and International Procurement Investment Potential in Domestic Manufacturing and New Supplier Participation Opportunities Arising from Gender-Neutral and Catch-Up Vaccination Programs Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Role of HPV Vaccination in Cervical Cancer Prevention and Other HPV-Associated Disease Prevention Strategic Importance of National Immunization Programs and Adolescent Vaccination Impact of Vaccine Valency, Dosing Policies, and Manufacturer Competition Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Assessment of Manufacturer Disclosures, Government Procurement, and Immunization Coverage Review of WHO Prequalification and National Regulatory Information Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Public Health Factors Expansion of Publicly Funded HPV Vaccination Programs Increasing Adoption of Single-Dose Vaccination Schedules Growth in International Procurement Eligibility and WHO Prequalification Expansion of Gender-Neutral and Catch-Up Vaccination Impact of Vaccine Pricing, Procurement Commitments, and Supply Reliability Competition Between Established Manufacturers and New Vaccine Suppliers Global Human Papillomavirus (HPV) Vaccine Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Vaccine Type: Nonavalent Vaccines Quadrivalent Vaccines Bivalent Vaccines Market Analysis by Technology: VLP-Based Vaccines Other Recombinant Protein-Based Approaches Market Analysis by Indication: Cervical Cancer Prevention Anal Cancer Prevention Genital Warts Prevention Other HPV-Associated Cancer Prevention Market Analysis by End User: Government Programs Hospitals Clinics Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Human Papillomavirus (HPV) Vaccine Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Vaccine Type, Technology, Indication, and End User National Immunization Recommendations and Catch-Up Vaccination Initiatives Country-Level Breakdown: United States Canada Mexico Europe Human Papillomavirus (HPV) Vaccine Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Vaccine Type, Technology, Indication, and End User Gender-Neutral Immunization Policies and Cervical Cancer Prevention Strategies Country-Level Breakdown: Germany United Kingdom France Italy Spain Sweden Rest of Europe Asia-Pacific Human Papillomavirus (HPV) Vaccine Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Vaccine Type, Technology, Indication, and End User National Immunization Program Expansion and Domestic Vaccine Manufacturing Market Opportunities from Improved Vaccine Accessibility and Adolescent Immunization Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Human Papillomavirus (HPV) Vaccine Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Vaccine Type, Technology, Indication, and End User Public Immunization Initiatives and School-Based Vaccination Delivery Catch-Up Vaccination and Adolescent Coverage Expansion Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Vaccine Type, Technology, Indication, and End User Introduction and Expansion of National HPV Vaccination Programs International Vaccine-Access Initiatives and Public Procurement School-Based Immunization and Cervical Cancer Prevention Priorities Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Burundi Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Merck & Co., Inc. GSK plc Xiamen Innovax Biotech Co., Ltd. Walvax Biotechnology Co., Ltd. Serum Institute of India Pvt. Ltd. Shanghai Zerun Biotechnology Co., Ltd. Jiangsu Recbio Technology Co., Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Incepta Pharmaceuticals Ltd. Competitive Landscape and Strategic Insights Benchmarking Based on Vaccine Portfolios, Vaccine Valency, Product Availability, and Regional Presence Supplier Qualification and Regulatory Compliance Capability Analysis WHO Prequalification and International Procurement Eligibility Nonavalent Vaccine Portfolio Positioning Quadrivalent and Bivalent Vaccine Competitive Positioning VLP-Based Vaccine Technology and Recombinant Protein-Based Approaches Manufacturing Capacity, Supply Reliability, and Procurement Pricing Strategies National Immunization Program Participation and Government Contract Analysis Single-Dose Vaccination and Product Presentation Strategies Appendix Abbreviations and Terminologies Used in the Report References and Sources WHO HPV Vaccine Product and Prequalification Information National Immunization Policy and Government Procurement References Manufacturer Product and Regulatory Information List of Tables Market Size by Vaccine Type, Technology, Indication, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Vaccine Type, Technology, Indication, and End User (2026–2032) Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Nonavalent, Quadrivalent, and Bivalent Vaccine Portfolio Comparison VLP-Based Vaccines and Other Recombinant Protein-Based Approaches Indication-Based Market Segmentation and HPV-Associated Disease Prevention Government Programs, Hospitals, and Clinics Market Analysis Competitive Benchmarking of Leading HPV Vaccine Manufacturers WHO Prequalification, Vaccine Presentations, and International Procurement Analysis National HPV Immunization Program and Vaccine Procurement Developments List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Vaccine Type, Technology, Indication, and End User (2025 vs. 2032) Global HPV Vaccine Ecosystem and Value Chain Analysis National HPV Vaccination Program Expansion and Global Coverage Trends Regional HPV Vaccine Procurement and Supplier Participation Vaccine Valency and Technology Positioning Across Established and Emerging Markets Single-Dose Vaccination and Gender-Neutral Immunization Trends